Louis Moore Bacon's DMII Position Overview
Louis Moore Bacon (via Moore Capital Management, Lp) currently holds 750,000 shares of Drugs Made In America Acquisition II Corp. (DMII) worth $7.42 M, representing 0.11% of the portfolio. First purchased in 2025-Q4, this recently established position has been held for 1 quarters.
Based on recent 13F filings, Louis Moore Bacon has initiated a new position in DMII, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.
Analysis based on 13F filings available since 2013 Q2
Louis Moore Bacon's Drugs Made In America Acquisition II (DMII) Holding Value Over Time
Track share changes against reported price movement
Quarterly Drugs Made In America Acquisition II (DMII) Trades by Louis Moore Bacon
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +750,000 | New Buy | 750,000 | $9.90 |
Louis Moore Bacon's Drugs Made In America Acquisition II Investment FAQs
Louis Moore Bacon first purchased Drugs Made In America Acquisition II Corp. (DMII) in Q4 2025, acquiring 750,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Louis Moore Bacon has held Drugs Made In America Acquisition II Corp. (DMII) for 1 quarters since Q4 2025.
Louis Moore Bacon's largest addition to Drugs Made In America Acquisition II Corp. (DMII) was in Q4 2025, adding 750,000 shares worth $7.42 M.
According to the latest 13F filing for Q4 2025, Louis Moore Bacon's firm, Moore Capital Management, Lp, owns 750,000 shares of Drugs Made In America Acquisition II Corp. (DMII), valued at approximately $7.42 M.
As of the Q4 2025 filing, Drugs Made In America Acquisition II Corp. (DMII) represents approximately 0.11% of Louis Moore Bacon's publicly disclosed stock portfolio, making it one of their key holdings.
Louis Moore Bacon's peak holding in Drugs Made In America Acquisition II Corp. (DMII) was 750,000 shares, as reported at the end of Q4 2025.